YusufMendaMD

Nuclear Medicine • Iowa City, IA

Associate Professor, Radiology, University of Iowa College of Medicine

Join to view full profile

Dr. Menda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Menda's full profile

Already have an account?

Office
200 Hawkins Dr
Iowa City, IA 52242
Phone+1 319-356-3214

Fax+1 319-356-2220

Education & Training

University of Iowa Hospitals and ClinicsResidency, Nuclear Medicine, 1998 - 2000
Istanbul University FomClass of 1994

Certifications & Licensure

IA State Medical License 2001 - 2026
American Board of Nuclear Medicine Nuclear Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer Start of enrollment: 2005 Oct 01
Completed
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients Start of enrollment: 2008 Mar 01
Completed
Phase 2
Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer Start of enrollment: 2009 Jul 01
Withdrawn
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Start of enrollment: 2012 Oct 01
Completed
Phase 2
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors Start of enrollment: 2017 Nov 03
Active, not recruiting
Early Phase 1
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Start of enrollment: 2022 Sep 30
Withdrawn
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibit...
Spenser S Johnson, Dijie Liu, Jordan T Ewald, Claudia Robles-Planells, Casey Pulliam
Cancer Biology & Therapy. 2024-12-31
Inter- and intra-tumoral heterogeneity on [Ga]Ga-DOTA-TATE/[Ga]Ga-DOTA-TOC PET/CT predicts response to [Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients.
Camila Gadens Zamboni, Ayca Dundar, Sanchay Jain, Marc Kruzer, Bradley T Loeffler
EJNMMI Reports. 2024-11-30
ASO Visual Abstract: Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.
Luis C Borbon, Scott K Sherman, Patrick J Breheny, Chandrikha Chandrasekharan, Yusuf Menda
Annals of Surgical Oncology. 2024-11-23

Press Mentions

A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy (RPT): An ASTRO Consensus DocumentNovember 26th, 2020
UI Neuroendocrine Tumor Program Earns High European DistinctionMarch 11th, 2019
UI Neuroendocrine Tumor Program Earns High European DistinctionMarch 11th, 2019
Join now to see all